Biogen posts marginal rise in first-quarter sales

Biogen Inc posted a 1.3% rise in first-quarter sales on Wednesday, helped by demand for its spinal muscular atrophy drug as well as its multiple sclerosis treatment, Tecfidera.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.